N2OFF shares surge 49.70% premarket as MitoCareX Bio reports positive in vitro anti-inflammatory data in human immune cells.

N2OFF Inc. surged 49.70% in premarket trading following the announcement that its subsidiary MitoCareX Bio reported preliminary in vitro data showing selected small-molecule candidates reduced pro-inflammatory markers in human immune cells. The MITOLINE™ platform’s ability to model mitochondrial carriers and identify anti-inflammatory compounds positions the company to target a market projected to exceed $120 billion by 2030. These results validate mitochondrial carrier modulation as a therapeutic strategy for inflammatory metabolic diseases, accelerating pre-clinical plans and attracting investor optimism about commercial potential.